Efficacy and safety of newer P2Y₁₂ inhibitors for acute coronary syndrome: a network meta-analysis.

ABSTRACT: Whether newer P2Y₁₂ inhibitors are more efficacious and safer than clopidogrel and whether there is a superior one remain uncertain. We compared the effect of P2Y₁₂ inhibitors on clinical outcomes in patients with acute coronary syndrome (ACS). Randomized controlled trials comparing clopidogrel, prasugrel, ticagrelor, or cangrelor, in combination with aspirin were searched. Sixteen trials with altogether 77,896 patients were included. Compared to clopidogrel, cardiovascular mortality was reduced with prasugrel (OR 0.85, 95% CI 0.75-0.97) and ticagrelor (0.82, 0.73-0.93). Myocardial infarction (0.75, 0.63-0.89) and major adverse cardiovascular events (0.80, 0.69-0.94) were reduced by prasugrel. Stent thrombosis was reduced by prasugrel (0.49, 0.38-0.63), ticagrelor (0.

SUBMITTER: Fei Y 

PROVIDER: S-EPMC7545197 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature